Signs of dehydration include dark urine, dry mouth, headaches, dizziness, and decreased urine output
Activation of GLP-1 receptors causes appetite suppression, reduces glucagon secretion, boosts insulin secretion (in a glucose-dependent manner), and slows down gastric emptying

The most commonly reported psychological symptoms include: Mood changes and irritability Some patients describe feeling more emotionally labile, experiencing mood swings, or becoming more easily frustrated during treatment Anxiety symptoms Reports of increased worry, restlessness, or generalised anxiety have been documented, though these may also relate to lifestyle changes or pre-existing tendencies Depressive symptoms A subset of patients report low mood, loss of interest in activities, or feelings of sadness Suicidal ideation Rare reports of suicidal thoughts have been investigated by regulatory authorities, though no causal relationship has been established In the pivotal STEP clinical trial programme for Wegovy, psychiatric adverse events were generally low and similar between the semaglutide and placebo groups
Both are 99%+ purity verified by HPLC, supplied as a white and blue-tinted lyophilized powder, and stored cool and dry (refrigerated after reconstitution)